Compare Dolby Laboratories, Inc. (DLB) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs GSK plc — how do they compare? Dolby Laboratories, Inc. trades at $58.63 (market cap $5.47B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 16.8× Dolby Laboratories, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and GSK plc for 93 Days on average.
| DLB | GSK | |
|---|---|---|
Market Cap | $5.47B | $91.88B |
Volume | 1,058,284 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $70.09 | $61.18 |
52-Week Low | $48.51 | $43.24 |
Typical Hold Time | 98 Days | 93 Days |
Enterprise Value | $4.85B | $111.88B |
Dividend Yield | 2.46% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.67, up 0.55% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 87.61% gross margins and 16.7% net income margins, though revenue has remained flat around $1.3B. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten.
DLB offers value with analyst consensus target of $90.33 (54% upside) but faces near-term execution risks and licensing volatility. The stock trades at reasonable valuations (P/E 24.87, P/S 4.15) with solid cash flow generation, though technical indicators suggest caution amid bearish momentum signals.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
